The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia

Francis J. Giles; Gautam Borthakur; Farhad Ravandi; Stefan Faderl; Srdan Verstovsek; Deborah Thomas; William Wierda; Alessandra Ferrajoli; Steven Kornblau; Sherry Pierce; Maher Albitar; Jorge Cortes; Hagop Kantarjian

doi:10.1111/j.1365-2141.2006.06476.x

The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia

Francis J. Giles, Gautam Borthakur, Farhad Ravandi, Stefan Faderl, Srdan Verstovsek, Deborah Thomas, William Wierda, Alessandra Ferrajoli, Steven Kornblau, Sherry Pierce, Maher Albitar, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journal › Article › peer-review

202 Scopus citations

Abstract

The haematopoietic cell transplantation comorbidity index (HCTCI) predicts nonrelapse mortality and overall survival (OS) post-stem cell transplantation. HCTCI scores were assessed in 177 patients over 60 years of age receiving acute myeloid leukaemia (AML) induction therapy. HCTCI score was 0 in 22% of patients, 1-2 in 30%, and ≥3 in 48%. In patients with scores of 0, 1-2, or ≥3, early death rates were 3%, 11% and 29% (P < 0.001) respectively; median OS was 45, 31 and 19 weeks (P = 0.04) respectively. The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy.

Original language	English (US)
Pages (from-to)	624-627
Number of pages	4
Journal	British Journal of Haematology
Volume	136
Issue number	4
DOIs	https://doi.org/10.1111/j.1365-2141.2006.06476.x
State	Published - Feb 2007
Externally published	Yes

Keywords

Acute myeloid leukaemia
Comorbidity
Induction chemotherapy
Prognosis

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/j.1365-2141.2006.06476.x

Cite this

Giles, F. J., Borthakur, G., Ravandi, F., Faderl, S., Verstovsek, S., Thomas, D., Wierda, W., Ferrajoli, A., Kornblau, S., Pierce, S., Albitar, M., Cortes, J., & Kantarjian, H. (2007). The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. British Journal of Haematology, 136(4), 624-627. https://doi.org/10.1111/j.1365-2141.2006.06476.x

The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. / Giles, Francis J.; Borthakur, Gautam; Ravandi, Farhad et al.
In: British Journal of Haematology, Vol. 136, No. 4, 02.2007, p. 624-627.

Research output: Contribution to journal › Article › peer-review

Giles, FJ, Borthakur, G, Ravandi, F, Faderl, S, Verstovsek, S, Thomas, D, Wierda, W, Ferrajoli, A, Kornblau, S, Pierce, S, Albitar, M, Cortes, J & Kantarjian, H 2007, 'The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia', British Journal of Haematology, vol. 136, no. 4, pp. 624-627. https://doi.org/10.1111/j.1365-2141.2006.06476.x

@article{efc482b2b9044536bc1581611959e46b,

title = "The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia",

abstract = "The haematopoietic cell transplantation comorbidity index (HCTCI) predicts nonrelapse mortality and overall survival (OS) post-stem cell transplantation. HCTCI scores were assessed in 177 patients over 60 years of age receiving acute myeloid leukaemia (AML) induction therapy. HCTCI score was 0 in 22% of patients, 1-2 in 30%, and ≥3 in 48%. In patients with scores of 0, 1-2, or ≥3, early death rates were 3%, 11% and 29% (P < 0.001) respectively; median OS was 45, 31 and 19 weeks (P = 0.04) respectively. The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy.",

keywords = "Acute myeloid leukaemia, Comorbidity, Induction chemotherapy, Prognosis",

author = "Giles, {Francis J.} and Gautam Borthakur and Farhad Ravandi and Stefan Faderl and Srdan Verstovsek and Deborah Thomas and William Wierda and Alessandra Ferrajoli and Steven Kornblau and Sherry Pierce and Maher Albitar and Jorge Cortes and Hagop Kantarjian",

year = "2007",

month = feb,

doi = "10.1111/j.1365-2141.2006.06476.x",

language = "English (US)",

volume = "136",

pages = "624--627",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia

AU - Giles, Francis J.

AU - Borthakur, Gautam

AU - Ravandi, Farhad

AU - Faderl, Stefan

AU - Verstovsek, Srdan

AU - Thomas, Deborah

AU - Wierda, William

AU - Ferrajoli, Alessandra

AU - Kornblau, Steven

AU - Pierce, Sherry

AU - Albitar, Maher

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2007/2

Y1 - 2007/2

N2 - The haematopoietic cell transplantation comorbidity index (HCTCI) predicts nonrelapse mortality and overall survival (OS) post-stem cell transplantation. HCTCI scores were assessed in 177 patients over 60 years of age receiving acute myeloid leukaemia (AML) induction therapy. HCTCI score was 0 in 22% of patients, 1-2 in 30%, and ≥3 in 48%. In patients with scores of 0, 1-2, or ≥3, early death rates were 3%, 11% and 29% (P < 0.001) respectively; median OS was 45, 31 and 19 weeks (P = 0.04) respectively. The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy.

AB - The haematopoietic cell transplantation comorbidity index (HCTCI) predicts nonrelapse mortality and overall survival (OS) post-stem cell transplantation. HCTCI scores were assessed in 177 patients over 60 years of age receiving acute myeloid leukaemia (AML) induction therapy. HCTCI score was 0 in 22% of patients, 1-2 in 30%, and ≥3 in 48%. In patients with scores of 0, 1-2, or ≥3, early death rates were 3%, 11% and 29% (P < 0.001) respectively; median OS was 45, 31 and 19 weeks (P = 0.04) respectively. The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy.

KW - Acute myeloid leukaemia

KW - Comorbidity

KW - Induction chemotherapy

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=33846433493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846433493&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2006.06476.x

DO - 10.1111/j.1365-2141.2006.06476.x

M3 - Article

C2 - 17223919

AN - SCOPUS:33846433493

SN - 0007-1048

VL - 136

SP - 624

EP - 627

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this